Vor Biopharma (VOR) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $19.34, +3.15% vs the prior close of $18.75.
- Volume 696.60K shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
VOR jumps 3.1% to $19.34. Closed at $19.34, +3.15% vs the prior close of $18.75. Day range $18.78–$20.25, opened at $18.85.
VOR daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — VOR jumps 3.1% to $19.34
- Closed at $19.34, +3.15% vs the prior close of $18.75. Day range $18.78–$20.25, opened at $18.85.
- Volume was 696.60K shares, 0.7x its 50-day average of 998.82K.
- Price is -10.7% vs its 50-day average ($21.66) and +13.8% vs its 200-day average ($16.99).
- 52-week range $6.50–$33.42; today's close sits at 48% of that range, 42.1% below the 52-week high.
Oct 14, 2026 — VOR dips 1.6% to $18.75, 3 down days in a row
- Closed at $18.75, -1.63% vs the prior close of $19.06. Day range $18.55–$19.74, opened at $18.79.
- Volume was 926.90K shares, 0.9x its 50-day average of 996.98K.
- Price is -13.7% vs its 50-day average ($21.72) and +10.5% vs its 200-day average ($16.96).
- 52-week range $6.50–$33.42; today's close sits at 46% of that range, 43.9% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — VOR slides 3.7% to $19.06
- Closed at $19.06, -3.74% vs the prior close of $19.80. Day range $18.98–$19.95, opened at $19.50.
- Volume was 949.40K shares, 1.0x its 50-day average of 995.02K.
- Price is -12.5% vs its 50-day average ($21.79) and +12.5% vs its 200-day average ($16.94).
- 52-week range $6.50–$33.42; today's close sits at 47% of that range, 43.0% below the 52-week high.
Oct 12, 2026 — VOR dips 0.5% to $19.80
- Closed at $19.80, -0.50% vs the prior close of $19.90. Day range $19.55–$20.52, opened at $19.79.
- Volume was 867.40K shares, 0.9x its 50-day average of 995.78K.
- Price is -9.3% vs its 50-day average ($21.84) and +17.0% vs its 200-day average ($16.92).
- 52-week range $6.50–$33.50; today's close sits at 49% of that range, 40.9% below the 52-week high.
Oct 9, 2026 — VOR jumps 4.0% to $19.90, 3 up days in a row
- Closed at $19.90, +4.03% vs the prior close of $19.13. Day range $18.85–$20.27, opened at $18.99.
- Volume was 1.10M shares, 1.1x its 50-day average of 992.19K.
- Price is -9.0% vs its 50-day average ($21.86) and +17.8% vs its 200-day average ($16.89).
- 52-week range $6.50–$33.50; today's close sits at 50% of that range, 40.6% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — VOR rises 1.9% to $19.13
- Closed at $19.13, +1.86% vs the prior close of $18.78. Day range $18.08–$19.88, opened at $18.64.
- Volume was 1.41M shares, 1.4x its 50-day average of 981.76K.
- Price is -12.6% vs its 50-day average ($21.90) and +13.5% vs its 200-day average ($16.86).
- 52-week range $6.50–$34.63; today's close sits at 45% of that range, 44.8% below the 52-week high.
Oct 7, 2026 — VOR rises 2.6% to $18.78
- Closed at $18.78, +2.57% vs the prior close of $18.31. Day range $17.86–$18.90, opened at $18.09.
- Volume was 563.10K shares, 0.6x its 50-day average of 987.80K — lighter than usual.
- Price is -14.3% vs its 50-day average ($21.91) and +11.6% vs its 200-day average ($16.83).
- 52-week range $6.50–$35.82; today's close sits at 42% of that range, 47.6% below the 52-week high.
Oct 6, 2026 — VOR dips 1.5% to $18.31
- Closed at $18.31, -1.45% vs the prior close of $18.58. Day range $17.97–$18.87, opened at $18.85.
- Volume was 472.80K shares, 0.5x its 50-day average of 997.30K — lighter than usual.
- Price is -16.5% vs its 50-day average ($21.93) and +9.0% vs its 200-day average ($16.80).
- 52-week range $6.50–$38.31; today's close sits at 37% of that range, 52.2% below the 52-week high.
Oct 5, 2026 — VOR dips 0.6% to $18.58
- Closed at $18.58, -0.59% vs the prior close of $18.69. Day range $18.07–$19.18, opened at $18.63.
- Volume was 648.50K shares, 0.7x its 50-day average of 997.11K.
- Price is -15.4% vs its 50-day average ($21.96) and +10.8% vs its 200-day average ($16.78).
- 52-week range $6.50–$39.49; today's close sits at 37% of that range, 53.0% below the 52-week high.
Oct 2, 2026 — VOR jumps 3.5% to $18.69
- Closed at $18.69, +3.49% vs the prior close of $18.06. Day range $18.09–$18.99, opened at $18.09.
- Volume was 773.30K shares, 0.8x its 50-day average of 992.71K.
- Price is -14.9% vs its 50-day average ($21.97) and +11.5% vs its 200-day average ($16.76).
- 52-week range $6.50–$42.75; today's close sits at 34% of that range, 56.3% below the 52-week high.
VOR latest news & SEC filings
Every SEC filing by or about VOR in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ra Capital Management, L.P. & Ra Capital Healthcare Fund Lp & Kolchinsky Peter & Shah Rajeev M. converted options/RSUs into 500 shares at $12.80 (≈$6.40K) on Oct 2, 2026; now holds 500
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 4, 2026 · Form S-3ASR — S-3ASR filing
S-3ASR filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 26, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$62.81M (prior year -$1.57B) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$1.16 (prior year -$251.24) (loss narrowed vs Jun 30, 2025)
Aug 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 30, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 21, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 21, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Shah Rajeev M. sold 213 shares at $19.75 (≈$4.21K) on Jul 16, 2026
- Ra Capital Management, L.P. sold 213 shares at $19.75 (≈$4.21K) on Jul 16, 2026
- Kolchinsky Peter sold 213 shares at $19.75 (≈$4.21K) on Jul 16, 2026
- Ra Capital Healthcare Fund Lp sold 213 shares at $19.75 (≈$4.21K) on Jul 16, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 9, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Things to know before you trade VOR
- Last results release: Jan 12, 2026 (8-K Item 2.02).
- How much it moves: over the last 20 sessions the average daily move was 2.79% (largest 12.0%).
- Liquidity: about 1.32M shares (≈$25.46M) trade per day on average.
- 52-week position: $19.34 vs a range of $6.50–$33.42 (48% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:20 on Sep 19, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Rajeev M. Shah sold 213 shares on Jul 16, 2026.
- Latest filings: 10-Q Aug 11, 2026; 8-K Jul 7, 2026; 8-K Jun 12, 2026.
- Share count: 59.16M shares outstanding (Aug 6, 2026), -53.3% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
VOR market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 18.85 | 20.25 | 18.78 | 19.34 | 696.60K |
| Oct 14, 2026 | 18.79 | 19.74 | 18.55 | 18.75 | 926.90K |
| Oct 13, 2026 | 19.50 | 19.95 | 18.98 | 19.06 | 949.40K |
| Oct 12, 2026 | 19.79 | 20.52 | 19.55 | 19.80 | 867.40K |
| Oct 9, 2026 | 18.99 | 20.27 | 18.85 | 19.90 | 1.10M |
| Oct 8, 2026 | 18.64 | 19.88 | 18.08 | 19.13 | 1.41M |
| Oct 7, 2026 | 18.09 | 18.90 | 17.86 | 18.78 | 563.10K |
| Oct 6, 2026 | 18.85 | 18.87 | 17.97 | 18.31 | 472.80K |
| Oct 5, 2026 | 18.63 | 19.18 | 18.07 | 18.58 | 648.50K |
| Oct 2, 2026 | 18.09 | 18.99 | 18.09 | 18.69 | 773.30K |
| Oct 1, 2026 | 18.97 | 19.30 | 18.00 | 18.06 | 876.20K |
| Sep 30, 2026 | 18.54 | 19.81 | 18.38 | 19.08 | 1.07M |
| Sep 29, 2026 | 18.63 | 18.77 | 17.52 | 18.33 | 1.38M |
| Sep 28, 2026 | 18.36 | 18.74 | 18.02 | 18.31 | 930.10K |
| Sep 25, 2026 | 18.62 | 18.71 | 17.95 | 18.52 | 792.80K |
| Sep 24, 2026 | 19.02 | 19.37 | 17.55 | 18.44 | 1.93M |
| Sep 23, 2026 | 22.00 | 22.02 | 18.89 | 19.37 | 2.76M |
| Sep 22, 2026 | 21.83 | 23.82 | 21.61 | 22.00 | 2.59M |
| Sep 21, 2026 | 21.82 | 22.16 | 21.44 | 21.89 | 1.86M |
| Sep 18, 2026 | 21.92 | 22.00 | 21.23 | 21.40 | 3.73M |
About Vor Biopharma
Vor Biopharma (VOR) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in BOSTON, MA. Fiscal year ends December 31. SEC CIK 1817229.
VOR board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Daniella Beckman | Director | Jun 12, 2026 |
| Alexander Cumbo | Director | Jun 12, 2026 |
| Michel Detheux | Director | Jun 12, 2026 |
| Wouter Joustra | Director | Jun 12, 2026 |
| Erez Kalir | Director | Jun 12, 2026 |
| Jean-Paul Kress | CEO and Chairman | Dec 9, 2025 |
| Andrew David Levin | Director | Jun 12, 2026 |
| Fouad Namouni | Director | Jun 12, 2026 |
| Capital Nexus Fund, L.P. Ra | Director | Oct 22, 2025 |
| David Zaccardelli | Director | Jul 9, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jean-Paul Kress | CEO and Chairman | Dec 9, 2025 |
| Sandesh Mahatme | CFO | Dec 9, 2025 |
| Jeremy Brett Sokolove | Chief Medical Officer | Apr 9, 2026 |
| Qing Che Zuraw | Chief Development Officer | Dec 9, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 16, 2026 | Rajeev M. Shah | Sale | 213 | $19.75 |
| Jul 16, 2026 | Capital Management, L.P. Ra | Sale | 213 | $19.75 |
| Jul 16, 2026 | Peter Kolchinsky | Sale | 213 | $19.75 |
| Jul 16, 2026 | Capital Healthcare Fund Lp Ra | Sale | 213 | $19.75 |
| Apr 22, 2026 | Rajeev M. Shah | Sale | 165,150 | $15.77 |
| Apr 22, 2026 | Capital Management, L.P. Ra | Sale | 165,150 | $15.77 |
| Apr 22, 2026 | Capital Healthcare Fund Lp Ra | Sale | 165,150 | $15.77 |
| Apr 22, 2026 | Peter Kolchinsky | Sale | 165,150 | $15.77 |
| Apr 20, 2026 | Capital Management, L.P. Ra | Sale | 171,963 | $15.77 |
| Apr 20, 2026 | Rajeev M. Shah | Sale | 171,963 | $15.77 |
| Apr 20, 2026 | Capital Healthcare Fund Lp Ra | Sale | 171,963 | $15.77 |
| Apr 20, 2026 | Peter Kolchinsky | Sale | 171,963 | $15.77 |
| Apr 17, 2026 | Capital Management, L.P. Ra | Sale | 458,411 | $16.28 |
| Apr 17, 2026 | Rajeev M. Shah | Sale | 458,411 | $16.28 |
| Apr 17, 2026 | Capital Healthcare Fund Lp Ra | Sale | 458,411 | $16.28 |
VOR financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-695.98M | -70.50 | $-142.71M |
| Dec 31, 2024 | — | $-116.91M | -34.03 | $-99.66M |
| Dec 31, 2023 | — | $-117.86M | -1.75 | $-100.29M |
| Dec 31, 2022 | — | $-92.09M | -2.33 | $-85.14M |
| Dec 31, 2021 | — | $-68.90M | -2.10 | $-69.14M |
Latest balance sheet: total assets $481.05M, total liabilities $681.25M, cash $107.86M (as of Jun 30, 2026).
VOR earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jan 12, 2026 | 8-K Item 2.02 (results) | $14.15 |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on VOR
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.